Garcinia gummi-gutta's Effect on Polycystic Ovary Syndrome-Induced in Rats and Its Anti-Obesity Properties

Lally Hanna  Luke; Anusha  R; Prasanna Bharathi  Sainath; Binoy Varghese  Cheriyan

doi:10.18502/tim.v10i1.18222

Lally Hanna Luke Department of Clinical Nutrition, MMM College of Health Sciences, Mogappair, Chennai, Tamil Nadu, 6000107, India
Anusha R Department of Clinical Nutrition, MMM College of Health Sciences, Mogappair, Chennai, Tamil Nadu, 6000107, India
Prasanna Bharathi Sainath Department of Pharmacology, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, 602105, India
Binoy Varghese Cheriyan Department of Pharmaceutical Chemistry, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India

DOI: https://doi.org/10.18502/tim.v10i1.18222

Keywords: Garcinia cambogia; Polycystic ovarian disease; Obesity; Luteinizing hormone; Uterus; Ovary; Pancreatic lipase

Abstract

This study evaluated the effects of Garcinia gummi-gutta (L.) N.Robson (GG) on polycystic ovary syndrome (PCO)-induced in rats and its anti-obesity properties. Fifteen Wistar rats were divided into three groups: control, 10 mg/kg Aqueous Extract of Garcinia gummi-gutta (AEGG), and 20 mg/kg AEGG. PCO was induced using Letrozole-oestradiol, confirmed by vaginal smear tests and weight gain. AEGG was screened for phenol (125.66±1.07 µg/mL) and flavonoid (102.66 ± 0.38 µg/ml) content, with its highest concentrations at 20 mg/mL. Pancreatic lipase inhibition showed AEGG’s anti-lipase effect (66.24%) at 100 μg/mL, compared to orlistat (98.7%) at 1 μg/ml. Rats received 20 mg/kg of AEGG demonstrated the highest significant reduction in body weight (203.8 g ±1.45 SD) and serum luteinizing hormone (LH) levels (1.24 mIU/mL) compared to the 10 mg/kg group and control group. Anatomical examination showed a normal uterus and reduced ovarian cysts in both AEGG-treated groups compared to the control. AEGG, particularly at 20 mg/kg, significantly reduced body weight, LH levels, and reproductive anatomy in PCO-induced rats, while demonstrating potential anti-obesity effects despite lower lipolytic activity compared to orlistat. The study suggests that AEGG at 20 mg/kg offers benefits in managing PCO and preventing obesity.